“…In cell lines of thyroid, ovarian, endometrial, and breast cancers, stimulation of GPER with E2 (Vivacqua et al, 2006a,b;Albanito et al, 2007) or other estrogenic compounds, such as genistein (Vivacqua et al, 2006a), bisphenol A (Dong et al, 2011;Chevalier et al, 2012a), or tamoxifen (Vivacqua et al, 2006b) activates signaling mechanisms that typically promote proliferation. Furthermore, in endometrial (Smith et al, 2007) and ovarian cancer (Smith et al, 2009), high GPER expression correlated with poor survival, although a recent study reported the opposite in ovarian cancer (Ignatov et al, 2013a).…”